ArticleJournal of clinical medicine2024

Uncovering the Differences: How DLQI and WHO-5 Scores Vary in Moderate-to-Severe Psoriasis Patients Treated with Tildrakizumab 100 mg vs. 200 mg?

Emanuele Trovato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.